Quintiles Library

Featured Fact Sheet

Retain patients in real-world studies
A patient-centric solution to provide stronger evidence Collecting patient-reported evidence for your observational studies is critical for demonstrating the safety and effectiveness of your therapies. To capture that data and produce a comprehensive picture of health outcomes, you need to engage patients over time and assist researchers in improving compliance. ...
Show Filters
Video 01:28
With Quintiles Patient-Centric Real-World Retention, you can retain patients throughout your real-world and late phase research while driving better reporting and compliance. Our expertise balances study design rigor with a differentiated and compelling patient experience. This is the player to use for single videos on Q.com...
Press Release
RESEARCH TRIANGLE PARK, NC – May 4, 2015 – Quintiles today announced the expansion of its bioanalytical laboratory services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) laboratory. The laboratory, which is located in Oss, the Netherlands, will have extensive bioanalytical testing capabilities and will provide a European facility for Quintiles customers to conduct pharmacokinetics studies.  The Oss laboratory facility combines a cohort of employees with extensive industry experience, automated processes, and a state-of-the-art facility equipped to increase high-quality throughput. The new laboratory is led by Dr. Benno Ingelse, an industry expert with more than 15 years of (bio)analytical experience.  In addition, the Oss...
Read More
Press Release
Research Triangle Park, NC - Quintiles CFO Kevin Gordon will present at the Bank of America Merrill Lynch 2015 Health Care Conference on Tuesday, May 12, 2015 in Las Vegas at the Encore Wynn. The Quintiles presentation will begin at 12:00 p.m. PDT. Investors may access a live audio webcast of the presentation on the Quintiles’ Investor Relations website at www.quintiles.com/investors. An archived audio version of the presentation will be available later that day. About Quintiles Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 33,000 employees conducting business in approximately 100 countries. We have helped develop or commercialize all of the top-75 best-selling drugs on the market....
Read More
Presentation
Quintiles will be presenting 15 posters and presentations on real-world data, hybrid studies, biosimilars and...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C. – May 1, 2015 – Quintiles Transnational Holdings Inc. (NYSE: Q) (the “Company” or “Quintiles”) announced today a proposed offering by its wholly owned subsidiary, Quintiles Transnational Corp. (“Quintiles Transnational”), of $800 million principal amount of senior unsecured notes due 2023 (the “Senior Notes”), subject to market and other conditions. The Senior Notes will be offered in a private placement that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Company intends to use the net proceeds of the offering, together with proceeds from its previously announced proposed new senior secured credit facility, to refinance its existing credit facilities, as well as for general corporate...
Read More
Brochure
At EA|Quintiles, you can rely on our experienced bioinformaticians to provide the analysis of RNA differential expression, variation and functional annotation for...
Read More
White Paper
The requirement for real-world evidence to support healthcare decision making has never been greater. This need, together with the increased availability of real-world data sources, has thrown light on the challenges of accessing and interpreting real-world data. Companies are looking for new approaches to gather real-world evidence at the right time, within the available budget, and to the appropriate quality standards. In this paper Louise Parmenter, Global Head of Operations, Epidemiology & Outcomes Research, Real-World & Late Phase Research and Anke van Engen, Principal, Advisory Services discuss strategies for success. Authors:  Louise Parmenter, Global Head of Operations, Epidemiology & Outcomes Research, Real-World & Late Phase Research at Quintiles Anke van Engen,...
Explore More
Fact Sheet
EA provides whole genome to focused set gene expression profiling and genotyping assays along with DNA and RNA sequencing services, sequence enrichment technologies and bioinformatics...
Read More
Fact Sheet
This Technical Note shows that advanced sample preparation and sequencing of RNA from FFPE samples produces similar results to samples that are...
Read More
Press Release
RESEARCH TRIANGLE PARK, N.C. – April 30, 2015 – Quintiles, the world’s largest biopharmaceutical services company, has been named to the InformationWeek Elite 100, a ranking of the top business technology innovators in the U.S. In compiling the InformationWeek Elite 100, the publication tracks the technology-based investments, strategies and results of some of the best-known organizations in the country.  Unique among corporate rankings, the Elite 100 spotlights the power of business technology innovation.  Quintiles was previously named to the InformationWeek 500 for five consecutive years. Accelerating the Clinical Trial Process:  Quintiles Infosario® Site Targeting Quintiles was named to the 2015 InformationWeek Elite 100 for its innovative Quintiles Infosario Site Targeting...
Read More
Scientific Poster
The authors undertook an observational, clinical study to explore the feasibility and potential clinical benefits of an upfront approach to the genomic profiling of tumors from metastatic colorectal cancer (mCRC)...
Explore More
Scientific Poster
VarPROWL is a great tool for detecting...
Explore More
Scientific Poster
Using exomes from The Cancer Genome Atlas, we apply this method to classify cancers into tissue-specific clusters. This model can thus be used with new tumor exomes to aid in identifying the tissue of-origin of the primary...
Explore More
Scientific Poster
The Genome Tissue Expression (GTEX) project6 can serve an adequate control for viral screening when no other controls are available. The use of normal controls enables differential expression methods to be used on viral quantification...
Explore More
Fact Sheet
A patient-centric solution to provide stronger evidence Collecting patient-reported evidence for your observational studies is critical for demonstrating the safety and effectiveness of your therapies. To capture that data and produce a comprehensive picture of health outcomes, you need to engage patients over time and assist researchers in improving...
Read More
Scientific Poster
Here we present the Quintiles Comprehensive Cancer Panel (QCCP): a CLIA validated assay for use with low input, FFPE material in addition to standard sample matrices that extensively covers over 200 genes and 17 breakpoints, focusing on 98% of the mutations found in...
Explore More
Press Release
RESEARCH TRIANGLE PARK, N.C., April 29, 2015 – Quintiles Transnational Holdings Inc. (the “Company” or “Quintiles”) (NYSE: Q) announced today that it is proposing, subject to market and other conditions, to enter into $1.75 billion of new senior secured credit facilities consisting of a $500 million revolving credit facility and $1.25 billion of term loans, and to issue $800 million aggregate principal amount of unsecured debt.  The Company intends to use the net proceeds of the offering of the unsecured debt, together with the new term loans, to refinance its existing credit facilities, as well as for general corporate purposes, including corporate transactions and equity repurchases.  The refinancing transactions would be entered by Quintiles Transnational Corp., the Company’s...
Read More
Press Release
Research Triangle Park, NC, April 29, 2015 – Quintiles Transnational Holdings Inc. (“Quintiles” or the “Company”) (NYSE: Q) today reported its financial results for the quarter ended March 31, 2015. $1.35 billion of net new business representing a 1.31 book-to-bill ratio 8.4% constant currency service revenue growth compared to the first quarter of 2014 $0.72 diluted adjusted earnings per share representing 5.9% growth compared to the first quarter of 2014 and first quarter GAAP reported diluted earnings per share of $0.68 Updating full year 2015 service revenue constant currency growth guidance to 7.0% - 8.0% compared to full year 2014 and reaffirming diluted adjusted EPS guidance of $3.02 - $3.13 per share, representing diluted adjusted EPS growth of 12% to 16% compared...
Read More
Expert
Today’s healthcare economy is becoming increasingly consumer-driven, as patients take greater responsibility for understanding their healthcare options, making decisions about their treatments and sharing their experience data. This consumer-driven mindset is also influencing patients’ expectations of participation in clinical research including real world and late phase...
Read More